Correspondence | Published:

Should preclinical studies be registered?

Nature Biotechnology volume 30, pages 488489 (2012) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Ann. Intern. Med. 147, 275–277 (2007).

  2. 2.

    Anonymous. Nat. Biotechnol. 30, 371 (2012).

  3. 3.

    , , , & PLoS Biol. 8, e1000344 (2010).

  4. 4.

    & Nat. Rev. Drug Discov. 3, 711–715 (2004).

  5. 5.

    The Aim and Structure of Physical Theory (Princeton University Press, Princeton, NJ; 1954).

  6. 6.

    et al. Br. J. Pharmacol. 157, 1157–1171 (2009).

  7. 7.

    & Shock 24, 107–119 (2005).

  8. 8.

    et al. Regul. Toxicol. Pharmacol. 50, 2–22 (2008).

  9. 9.

    et al. J. Pharmacol. Exp. Ther. 283, 46–58 (1997).

  10. 10.

    et al. Br. Med. J. 344, d7292 (2012).

  11. 11.

    et al. J. Am. Med. Assoc. 297, 2112–2120 (2007).

Download references

Author information

Affiliations

  1. Biomedical Ethics Unit, Department of Social Studies of Medicine, McGill University, Montreal, Quebec, Canada.

    • Jonathan Kimmelman
  2. National Core for Neuroethics, Division of Neurology, Faculty of Medicine, University of British Columbia, UBC Hospital, Vancouver, British Columbia, Canada.

    • James A Anderson

Authors

  1. Search for Jonathan Kimmelman in:

  2. Search for James A Anderson in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Jonathan Kimmelman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2261

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing